AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Stage III NSCLC RWE in Chinese Patients
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2019-07-18
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 500
- Registration Number
- NCT04023812
- Locations
- 🇨🇳
Research Site, Yin Chuan, China
Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 552
- Registration Number
- NCT04008706
- Locations
- 🇬🇧
Research Site, Newmarket, United Kingdom
Mass Balance Recovery, Pharmacokinetics and Metabolite Profile and Identification of [14C]AZD7594
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- Drug: Intravenous InfusionDrug: Inhaled dose
- First Posted Date
- 2019-06-28
- Last Posted Date
- 2019-07-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT04002427
- Locations
- 🇬🇧
Research Site, Ruddington, United Kingdom
Study of Exenatide Once-Weekly Suspension in Chinese Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2019-06-28
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT04001231
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
Phase 3
Active, not recruiting
- Conditions
- Triple Negative Breast Neoplasms
- Interventions
- First Posted Date
- 2019-06-25
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 923
- Registration Number
- NCT03997123
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLC
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2019-06-24
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 529
- Registration Number
- NCT03995875
- Locations
- 🇯🇵
Research Site, Wakayama, Japan
A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia
Phase 2
Completed
- Conditions
- Chronic Kidney Disease
- Interventions
- First Posted Date
- 2019-06-19
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 861
- Registration Number
- NCT03990363
- Locations
- 🇪🇸
Research Site, Valencia, Spain
A Study to Evaluate the Pharmacokinetics of Tezepelumab After Being Delivered by an Accessorized Pre Filled Syringe or Autoinjector Compared With Vial and Syringe in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- Biological: Tezepelumab
- First Posted Date
- 2019-06-18
- Last Posted Date
- 2020-01-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 315
- Registration Number
- NCT03989544
- Locations
- 🇩🇪
Research Site, Berlin, Germany
A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies
- First Posted Date
- 2019-06-10
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 10
- Registration Number
- NCT03980821
- Locations
- 🇯🇵
Research Site, Kashiwa, Japan
A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)
Phase 3
Completed
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3012
- Registration Number
- NCT03979313
- Locations
- 🇬🇧
Research Site, London, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath